However, indicative of the immunosuppressive nature of this model and in contrast to the immunogenic KPARG12C model, combined inhibition of both KRASG12C and SHP2 did not lead to tumour eradication, just delayed progression, suggestive of inadequate engagement of adaptive immunity. This evidence concerns the gene PTPN11 and neoplasm.